In a small trial, low-dose creatine improved reaction time in menopausal women

Creatine is the best-selling supplement in the gym, a cheap powder that lifters have used for decades to improve athletic performance and build muscle. Lately it has been promoted for something else: the aging brain, and the mental fog that can arrive with menopause.

Now a study in the Journal of the American Nutrition Association has put the idea to a proper test. Over eight weeks, 36 perimenopausal and menopausal women were randomly given creatine or a placebo, and the researchers tracked their thinking, their brain chemistry and their blood. At the middle dose, creatine came out ahead three ways: better reaction time, higher frontal brain creatine levels, and a healthier cholesterol profile.

What creatine is, and why the brain came up

Creatine is a compound that comes from three amino acids and that the body also gets from food, mainly seafood and red meat. Most of the creatine in the body is stored in muscle, with a little in the brain, where it helps to make energy quickly during short bursts of demand. That is why athletes take it. It is also why researchers also study creatine to see whether it helps the brain.

The reasoning for menopause runs through energy. The brain is a heavy user of it, and creatine is part of how cells cover sudden demand. The idea is that keeping the brain’s creatine topped up might support the mental work that can flag around this stage of life, though that chain of reasoning is still a hypothesis. What had been missing was a proper trial in these women. The new study set out to fill that gap, one of the first to test low-dose creatine as a targeted intervention for the neurocognitive and metabolic changes of menopause.

How strong is the evidence?

This was a randomized controlled double-blind trial, which means neither the women nor the researchers knew who was taking creatine and who was taking placebo. That design is a genuine strength: it can tell a real effect from wishful thinking. The weakness is size and length. It was small and short: 36 apparently healthy women, split into one of four groups, followed for just eight weeks. So this is a promising early signal rather than a settled answer. A single trial can point in a direction; it cannot prove the case, and these findings need larger and longer studies before anyone leans on them.

What the trial found

The benefits showed up with medium-dose creatine hydrochloride, about 1,500 milligrams a day; the lowest dose and a creatine blend did not stand out. At that dose, reaction time improved, frontal brain creatine levels rose while placebo barely changed, and the women’s cholesterol readings shifted in a healthier direction. There was also a possible edge in reducing the severity of mood swings, though that result was too weak to count as real. All the doses were well tolerated, with no severe side effects reported.

One number is worth holding onto: the effective dose was around 1,500 milligrams a day. That is a fraction of the 3 to 5 grams lifters take for muscle, yet it was enough to move a brain marker. A modest dose doing real work is part of what makes the result interesting.

The catch

Split into one of four groups, the 36 women left only about nine per treatment. With so few women in each arm, a single strong responder can sway the result, and eight weeks is a short window in which to judge either brain health or cholesterol. The volunteers were healthy, so the findings may not carry over to women already struggling with focus or recall. Reaction time is a narrow measure, too; it says little about memory or the broad brain fog the supplement is often sold to fix. And this is one trial from one research group. The full paper sits behind a paywall, so its detailed limitations could not be reviewed here.

Should you take creatine for this?

Not on the strength of this study alone. It is too small and too short to tell any woman that creatine will sharpen her mind. What it offers is a reason to take the question seriously, attached to a cheap, well-studied supplement that many people already use. The authors, from the group of creatine researcher Sergej Ostojic, conclude the approach “may be a promising, safe, effective, and practical dietary strategy for improving clinical outcomes and elevating brain creatine concentrations in perimenopausal and menopausal women.” Anyone thinking of trying it, especially at higher doses than the modest amount used here, should talk to their doctor first.

For now, it is an encouraging early result in a few dozen women, not a proven fix for the menopausal brain.